Mutations in the isocitrate dehydrogenase enzymes IDH1 and IDH2 have been associated with oncogenic transformation in several malignancies, including gliomas, acute myeloid leukemia (AML), cholangiocarcinoma and chondrosarcomas. Despite the approval of several mIDH1 inhibitors, suboptimal blood-brain barrier penetration and the development of acquired resistance limit their use.

Acute myeloid leukemia (AML) is an aggressive blood cancer with poor clinical outcomes and high mortality rates, primarily driven by drug resistance and relapse. Increasing evidence has confirmed dysregulated cellular metabolism as a tumor hallmark with crucial roles in tumor growth, progression and drug resistance.

Researchers from Xi’an Jiaotong University and Southern University of Science and Technology have conducted a comprehensive preclinical study to evaluate the efficacy and safety of a second-generation CAR T therapy targeting trophoblast cell-surface antigen 2 (TROP2) for the treatment of triple-negative breast cancer.

In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing therapies for viral infections, cancer, and genetic conditions. What happens to mRNA innovation when funding dries up? This series explores how reductions in funding could impact mRNA technology, affecting innovation, research and future therapies.

Dewpoint Therapeutics Inc. has closed its series D financing to advance DPTX-3186, a first-in-class condensate modulator (c-mod), into clinical trials by year-end and deliver early clinical proof of concept in gastric cancer by the end of next year.